Market Analysis on Personalized Medicine Biomarkers Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Personalized Medicine Biomarkers Market from 2024 to 2025?
The biomarkers market for personalized medicine has witnessed a significant expansion in recent times. The market value will surge from $22.85 billion in 2024 to $26.98 billion in 2025, displaying a compound annual growth rate (CAGR) of 18.0%. The exponential growth during the historic period was due to several factors such as the rising incidences of chronic illnesses, escalating use of companion diagnostics, increased funding in biomarker research, emphasis on early detection and preventive healthcare measures, along with regulatory backing for therapies based on biomarkers.
What Is the Projected Market Size of the Personalized Medicine Biomarkers Market?
In the coming years, the personalized medicine biomarkers market is projected to experience brisk expansion. The market size is set to surge to $51.53 billion in 2029, registering a compound annual growth rate (CAGR) of 17.6%. The accelerated growth during the forecast period is due to factors such as broadening application of precision oncology, heightened demand for targeted treatments, emphasis on early illness detection, increasing consumer preference for personalized methods, and encouraging government policies and funding. The forecast period will witness significant trends like a multi-omics technique for biomarker discovery, the evolution of liquid biopsy-based biomarkers, rising utilization of digital biomarkers, application of AI and machine learning in biomarker identification, and the use of real-world evidence in biomarker validation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp
Who are the Major Competitors in the Personalized Medicine Biomarkers Market Outlook?
Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
What Is Fueling Growth in the Personalized Medicine Biomarkers Market?
The increase in chronic illnesses is anticipated to drive the expansion of the personalized medicine biomarkers market. Chronic illnesses are prolonged medical issues that progress gradually, lasting for more than a year, and necessitate steady medical care while impacting daily routines. This increase can be attributed to poor lifestyle choices, subpar diets, inactive lifestyle, and elevated stress levels. Personalized medicine biomarkers provide a way to customise treatments for chronic diseases by identifying potent therapies, forecasting disease progression, and reducing negative side effects based on individual genetic and molecular profiles. For example, the World Health Organization (WHO), a Switzerland-based health body, stated in February 2024 that by 2050, the number of new cancer incidences is likely to exceed 35 million, marking a 77% increase from the projected 20 million cases in 2022. Hence, the rise in chronic diseases is stimulating the expansion of the personalized medicine biomarkers market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp
Which Personalized Medicine Biomarkers Market Segments Are Growing the Fastest?
The personalized medicine biomarkers market covered in this report is segmented –
1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types
2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications
3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring
4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users
Subsegments:
1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers
2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers
3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers
4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers
Which Industry Trends Are Shaping the Future of the Personalized Medicine Biomarkers Market?
Top-tier companies in the personalized medicine biomarkers industry are diligently working to secure regulatory approvals for their products. These approvals, granted by health authorities, verify that a medical product or treatment is safe, effective, and meets quality standards for public utilization. This strategy is employed to bolster the authenticity of their offerings, enlarge their market footprint, and boost patient results. For instance, Illumina, Inc., a leading biotech enterprise based in the US, was approved by the Food and Drug Administration (FDA) for its cancer biomarker test and two associated diagnostics in August 2024. They utilize next-generation sequencing (NGS) technology in their test to pinpoint genetic alterations in cancer cells. This assists medical professionals in determining the most effective treatment options based on unique biomarkers. The FDA’s approval of this test represents a substantial progression in precision oncology. Its ultimate goal is to amplify the rate of accuracy when choosing treatments for cancer patients, leading to superior personalized healthcare.
Access The Full Report Here:
Which Countries Are Leading the Personalized Medicine Biomarkers Market?
North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23471
This Report Delivers Insight On:
1. How big is the personalized medicine biomarkers market, and how is it changing globally?
2. Who are the major companies in the personalized medicine biomarkers market, and how are they performing?
3. What are the key opportunities and risks in the personalized medicine biomarkers market right now?
4. Which products or customer segments are growing the most in the personalized medicine biomarkers market?
5. What factors are helping or slowing down the growth of the personalized medicine biomarkers market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
